Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Vintafolide 2.5 mg|DRUG: Paclitaxel 80 mg/m^2|DRUG: Etarfolatide|DRUG: Folic acid|DRUG: Premedication for Paclitaxel
Sponsor: Endocyte